Please ensure Javascript is enabled for purposes of website accessibility

This News Has Foot Locker Stock Running Higher Today

By Jason Hall - Apr 29, 2020 at 2:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The athletic shoe and apparel retailer's shares have gained almost 52% since late March.

What happened?

Foot Locker, Inc. (FL 2.21%) shares are up almost 9% just before 3 p.m. EDT on April 29, having cooled off a little after surging nearly 10% earlier in the day. Like other retailers that focus on discretionary consumer goods, high hopes for a treatment for COVID-19 have investors looking at the company as a potential winner once the economy opens back up. 

So what

A potential anti-viral treatment for the novel coronavirus that causes COVID-19 could be a big boost in efforts to arrest the spread of this deadly disease. Gilead Sciences (GILD 0.82%) said a trial of remdesivir being run by the National Institutes of Allergy and Infectious Diseases, or NIAID, reached its endpoint, and separately reported that one of the trials it was running produced positive results. 

Surprised man holding model rocket that starts to launch.

Image source: Getty Images.

This potential good news in the fight against COVID-19 has investors looking for stocks that could benefit. Health experts say that without a widely available treatment or vaccine -- which is probably a year or more away at the earliest -- it will be almost impossible to fully reopen the economy, so investors today are speculating that remdesivir could be a huge step toward that goal. Hence the price of Foot Locker's stock moving up sharply. 

Now what

To put it bluntly, this is a big jump based entirely on speculation. Remdesivir has shown some potential as a treatment, but there's very limited data being released and it's still likely months before there's enough data to inform an accurate understanding of the drug's effectiveness. Even if it proves an effective treatment, it will take even more time to manufacture and distribute it to healthcare providers. 

In other words, there's a lot more that needs to happen before we even know if this is a treatment that will lead to unshackling the economy. 

It's nice to be hopeful, but hope isn't a very good investment thesis. Foot Locker has an e-commerce business, but the vast majority of its sales come from retail stores that are by and large shuttered. That's unlikely to change in a large way for many months to come, even if remdesivir and other drugs are identified as effective treatments. 

Put it all together, and today's speculative jump on potential good news for a treatment could get erased just as quickly on bad news tomorrow or the next day. Until we actually start seeing non-essential retail opened up in a broad way, Foot Locker is going to have a tough time of it. If you decide to invest in the company, be prepared to ride out a lot of volatility until we get to a point where the economy can actually come back online. That could be much later this year in many parts of the world than you expect. 

Jason Hall owns shares of Foot Locker. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Foot Locker, Inc. Stock Quote
Foot Locker, Inc.
FL
$31.52 (2.21%) $0.68
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.96 (0.82%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.